Improved clinical symptoms in three patients with spinocerebellar ataxia through a surgical decompression procedure of the posterior cranial fossa with subsequent flap transplantation of the cerebellum

Wagner, 2016, Gene, stem cell, and alternative therapies for SCA 1, Front Mol Neurosci, 9, 67, 10.3389/fnmol.2016.00067 Liu, 2018, Epigenetic profiles in polyglutamine disorders, Epigenomics, 10, 9, 10.2217/epi-2017-0089 Sequeiros, 2012, Epidemiology and population genetics of degenerative ataxias, Handb Clin Neurol, 103, 227, 10.1016/B978-0-444-51892-7.00014-0 Paradisi, 2016, Spinocerebellar ataxias in Venezuela: genetic epidemiology and their most likely ethnic descent, J Hum Genet, 61, 215, 10.1038/jhg.2015.131 Nakamura, 2015, Mesenchymal stem cells as a potential therapeutic tool for spinocerebellar ataxia, Cerebellum, 14, 165, 10.1007/s12311-014-0604-1 Ashizawa, 2018, Spinocerebellar ataxias: prospects and challenges for therapy development, Nat Rev Neurol, 14, 590, 10.1038/s41582-018-0051-6 Scoles, 2017, Antisense oligonucleotide therapy for spinocerebellar ataxia type 2, Nature, 544, 362, 10.1038/nature22044 Braga Neto, 2016, Current concepts in the treatment of hereditary ataxias, Arq Neuropsiquiatr, 74, 244, 10.1590/0004-282X20160038 Paulson, 2017, Polyglutamine spinocerebellar ataxias - from genes to potential treatments, Nat Rev Neurosci, 18, 613, 10.1038/nrn.2017.92 Evers, 2014, Ataxin-3 protein and RNA toxicity in spinocerebellar ataxia type 3: current insights and emerging therapeutic strategies, Mol Neurobiol, 49, 1513 Rüb, 2013, Clinical features, neurogenetics and neuropathology of the polyglutamine spinocerebellar ataxias type 1, 2, 3, 6 and 7, Prog Neurobiol, 104, 38, 10.1016/j.pneurobio.2013.01.001